Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women

Status Completed

Clinical Trial Summary

Sustainability of vaginal ultra-low dose estrogen therapy in postmenopausal women

Clinical Trial Description

Within this trial 50 postmenopausal women receive a vaginal estrogen therapy as treatment for symptomatic vaginal atrophy. The sustainability of vaginal estrogen therapy after the end of therapy has not yet been investigated. All participants will be asked to come for the following 7 visits. - Visit 1: Standard Gynecological examination; Inclusion and exclusion criteria check - Visit 2: Handing out of Gynoflor (estrogen) for a 6 weeks treatment. - Visit 3 (Study Start): After using the vaginal estrogen for 6 weeks, a vaginal swap will be done to measure the vaginal maturation index (VMI). The participants will also receive a questionnaire to define some subjective parameters. The parameters measured at visit 1 will count as reference. The estrogen therapy will now be sustained. - Visit 4-6: Measuring of the VMI and handing out the questionnaires to define subjective parameters. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02887885
Study type	Observational
Source	University Hospital Inselspital, Berne
Contact
Status	Completed
Phase
Start date	January 22, 2018
Completion date	April 10, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05448079` - The Effect of Sexual Counseling Given According to the PLISSIT Model on FSFI, MAS and SQOL-F of Postmenopausal Women	N/A
Completed	`NCT00745173` - Study Evaluating Premarin and Bazedoxifene Potential Interaction	Phase 1
Completed	`NCT00913926` - Effects of Wellnara on Climacteric Symptoms	N/A
Completed	`NCT00550433` - Study Evaluating Bazedoxifene/CE in Postmenopausal Women	Phase 1
Completed	`NCT00515593` - PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)	N/A
Completed	`NCT00381251` - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.	Phase 1
Completed	`NCT00185328` - Efficacy and Tolerability of Angeliq in Thai Women	Phase 4
Completed	`NCT00484107` - Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women	Phase 4
Completed	`NCT00023543` - Reduction of Triglycerides in Women on Hormone Replacement Therapy	Phase 2
Completed	`NCT00152282` - A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women	Phase 2
Completed	`NCT00006407` - Sex Steroid Hormones and Risk of CHD in Women	N/A
Completed	`NCT00010712` - Effects of Black Cohosh on Menopausal Hot Flashes	Phase 2
Completed	`NCT00006539` - Thrombotic, Inflammatory & Gene Markers of CVD in Women	N/A
Completed	`NCT00001752` - Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women	Phase 2
Completed	`NCT00005515` - Mutations, Hormone Therapy (HRT) and Venous Thromboembolism	N/A
Completed	`NCT00000481` - Women's Health Trial: Feasibility Study in Minority Populations	Phase 3
Completed	`NCT00000466` - Postmenopausal Estrogen/Progestin Interventions (PEPI)	Phase 3
Completed	`NCT00543634` - Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women	Phase 1
Completed	`NCT06115577` - Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes
Completed	`NCT01556737` - Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women	N/A